bevasiranib

Small moleculeexperimental

Clinical trial activity

5 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2004 (NCT00722384)

Timeline

2000s

Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Jan 1, 2007
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Toll-like receptor 3ACTIVATOR
Toll-like receptor 3 activator
- Toll-like receptor 3 (TLR3) ↗
Vascular endothelial growth factor AANTISENSE INHIBITOR
VEGFA antisense inhibitor
- Vascular endothelial growth factor A (VEGFA) ↗
VEGF-A mRNARNAI INHIBITOR
VEGF-A mRNA RNAi inhibitor

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O

Mol. weight: 6610.12 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL2110581 ↗

Also known as

bevasiranib
bevasiranib

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00557791	Phase 3	Nov 1, 2009	Opko
NCT00499590	Phase 3	Aug 1, 2007	Opko
NCT00306904	Phase 2	Jan 1, 2006	Chiltern International, Opko
NCT00259753	Phase 2	Jul 1, 2005	Opko
NCT00722384	Phase 1	Aug 1, 2004	Opko

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Opko	For profit	5	5	3	2004
Chiltern International	For profit	1	0	1	2006

2 organizations

Page 1 / 1